Key Points – Revenue rose modestly to $11.4 million in Q2, up 1.7% year over year, while TriSalus reiterated its 2026 revenue forecast of $54 million to $57 million.
The company more than doubled its commercial footprint during the first half of the year. – A new CMS G-code could expand reimbursement for TriNav pressure-enabled drug delivery in physician office-based labs, supporting potential growth in liver, uterine, prostate and genicular artery embolization procedures. – Gross margin improved to 86.8%, but higher sales and marketing costs from the expanded sales force widened the adjusted EBITDA loss to approximately $7.1 million
TriSalus ended the quarter with about $46.3 million in cash and said it expects sequential revenue improvement in the second half of 2026. TriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company reiterated its full-year 2026 revenue outlook of $54 million to $57 million, representing projected growth of 19% to 26% over 2025.
President and Chief Executive Officer Mary Szela said the quarter reflected progress in expanding the company’s commercial infrastructure, building clinical evidence for pressure-enabled drug delivery, or PEDD, and broadening the potential uses of its technology. TriSalus more than doubled its commercial footprint during the first half of the year, with the hiring initiative beginning in February and all new representatives in place by April. “We’re already seeing positive results from our commercial evolution in the form of ramping engagement and productivity,” Szela said. During the question-and-answer session, she said a number of the newly hired representatives were exceeding internal metrics and that second-quarter results came in according to the company’s internal operating model.